BetterLife Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BETR.CN research report →
Companywww.abetterlifepharma.com
BetterLife Pharma Inc. , a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections.
- CEO
- Ahmad Doroudian
- IPO
- 2017
- Employees
- 4
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $9.87M
- P/E
- -5.33
- P/S
- 0.00
- P/B
- -1.04
- EV/EBITDA
- -5.88
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 19.14%
- ROIC
- 35.99%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-3,520,288 · -21.85%
- EPS
- $-0.03 · -7.58%
- Op Income
- $-5,000,113
- FCF YoY
- 18.23%
Performance & Tape
- 52W High
- $0.12
- 52W Low
- $0.04
- 50D MA
- $0.07
- 200D MA
- $0.06
- Beta
- 0.54
- Avg Volume
- 99.86K
Get TickerSpark's AI analysis on BETR.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BETR.CN Coverage
We haven't published any research on BETR.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BETR.CN Report →